Latest Board Refresh News

Argo Investments reported a stable $260.2 million profit for FY2026 with fully franked dividends rising to 38.5 cents per share. The LIC maintains a conservative investment approach, low costs, and strong governance as it marks 80 years.

Nexalis Therapeutics reports a 52% rise in half-year losses to $1.3 million amid funding facility cancellation and clinical trial suspensions, highlighting ongoing cash flow challenges.

Yandal Resources shakes up its leadership with the appointment of seasoned geologist Eduard Eshuys as Non-Executive Chair and the departure of CEO Chris Oorschot, signaling a pivotal moment as the company advances its gold exploration projects in Western Australia.

Invex Therapeutics posted a $1.35 million net loss for FY2026, driven by expanded R&D efforts and a deepening collaboration with Tessara Therapeutics targeting neurological diseases including Alzheimer’s. The company renewed its orphan drug status in Europe and restructured its board during the year.

ClearVue Technologies saw a 35% revenue decline to $161,000 and a $11 million net loss in FY2026, driven by a major operational overhaul and significant product certification efforts. Despite the financial setback, the company expanded into new markets and secured key commercial projects.

BluGlass Limited reported a 5% reduction in its net loss to A$10.39 million for FY26 despite a 10% revenue dip, boosted by new US defence and industry contracts and a significant capital raise to fund growth.

OncoSil Medical lifted revenues 44% in FY26 to $1.68 million and trimmed losses by 28% to $10.86 million, buoyed by key regulatory approvals including FDA HDE and Australian TGA listings. The company is poised for commercial launches in the US and Australia, with strong clinical data underpinning its growth.

Comvita Limited has swung back to profitability in FY26, reporting $7.7 million net profit after a $40.5 million capital raise that brought Southeast Asian consumer giant F&N Ventures on board with a near 20% stake.

Clarity Pharmaceuticals reported a 67% increase in net loss to $107.2 million for FY26, driven by higher R&D spending, while advancing multiple Phase III trials and expanding manufacturing capacity ahead of commercialisation.

TALi Digital Limited (ASX: TD1) posted a 416% jump in revenue for FY26 but also recorded a $2.2 million loss driven by a $1.3 million impairment of its YCDI! intangible assets. The company is pursuing growth through AI-focused acquisitions and a $3.3 million capital raise.

Piche Resources completed a $2.53 million entitlement offer, raising $728,324 from shareholders, with the underwriter stepping in to cover a $1.85 million shortfall. New shares and options are set to trade from 31 August 2026.

AMA Group Limited (ASX: AMA) reversed losses with a statutory profit of AUD 7.7 million in FY26, driven by revenue growth and operational improvements across key segments. The company declared a fully franked dividend, its first since 2019, and outlined a positive outlook for FY27.